A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Clinical trial NCT04882072 · TERMINATED

Trial details

NCT number: NCT04882072
Sponsor: Janssen Pharmaceutical K.K.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Takayasu Arteritis

Start date: 2021-09-15
Primary completion: 2023-05-25
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.